←
Gustafson Group @ Stony Brook514 posts
Gustafson Group @ Stony Brook avatar

Gustafson Group @ Stony Brook

@GustafsonLab

Asymmetric Synthesis and Chemical Biology

◷ Joined June 2017▧ 51 Photos and videos
Jeff Lipshultz avatar
⟳ Gustafson Group @ Stony Brook retweeted
Jeff Lipshultz@jeflip·Oct 31

Our department (@StonyBrookChem) is hiring! We are looking to recruit an Empire Innovation Professor (Assoc or Full) in the purposefully broad area of "Molecules and Materials for Quantum Information Sciences". Deadline is Nov 27. Come join us! apply.interfolio.com/195153

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·Oct 13

One thing worth mentioning is the majority of examples utilized tried and true chiral resolution chemistry, however there was a lot of innovation in recycling of the unwanted atropisomer. There were also a few examples of asymmetric catalysis being employed.

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·Oct 13

While putting this together we found at least two dozen confirmed stable atropisomers that are currently undergoing clinical trials. This inspired to hone in on the ones with disclosed syntheses and look how the chiral axis was set.

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·Oct 13

We did a thing! pubs.rsc.org/ob/article/doi/… This review, which is part of a themed collection on axially chirality, was written with the goal of sharing some fundamentals and capturing a 'snapshot' of the state of atropisomerism in drug discovery.

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 12

The S-Atropisomer* had no KIT activity, but displayed intriguing selectivity towards LYN kinase, an emerging target for the treatment of cancer, autoimmune diseases and inflammatory conditions, that currently lacks highly selective inhibitors.

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 12

The R-atropisomer* maintained potency against cellular models of GIST (IC50 < 10 nM) while displaying improved target selectivity, including towards key oncogenic c-KIT mutants. *Cahn-Ingold-Prelog priorities cause the analogs to have opposite stereochemical descriptors.*

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 12

We analyzed a ‘conformational map’ of privileged heterocycles and found that the multi kinase inhibitor ripretinib interacted with c-KIT, KIT’s target for GIST, in an atropisomeric R conformation. This led us to make class-3 atropisomeric analogs of ripretinib.

Post attachment
Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 12

Another day another preprint on ChemRxiv! “Leveraging Atropisomerism to Obtain a Mutant-Selective c-KIT Inhibitor in Gastrointestinal Stromal Tumors” A story of privileged heterocycles, atropisomerism and kinase selectivity. chemrxiv.org/doi/full/10.264…

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 11

This led us to introduce a peri Fluoro group as a H-bonding handle to ‘lock’ that axis into the trans conformation. This seemingly simple modification led to a dramatic increase in HER selectivity, particularly towards HER4, a kinase with emerging implications in ovarian cancer.

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 11

The ‘conformational mapping’ of diarylamine crystal structures suggested that the pan-HER kinase inhibitor neratinib adopts two planar conformations around a C–N axes (similar to cis and trans alkenes). HER family kinases generally preferred the ‘trans’ conformation

Post attachment
Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·May 11

Excited to share our new ChemRxiv preprint: “Leveraging Conformational Control of Neratinib’s C–N Axes to Enhance HER4 Selectivity in Ovarian Cancer” congrats to the tam @StonyBrookChem and @SDSUChemBiochem Read here: doi.org/10.26434/chemrxiv.15…

Gustafson Group @ Stony Brook avatar
Gustafson Group @ Stony Brook@GustafsonLab·Mar 6

The final version of this manuscript is up at @ACSCatalysis pubs.acs.org/doi/10.1021/acs…

I am sharing this preprint from my group. Inspired by all the great recent skeletal editing work, we developed an atropisomer selective strategy to take Indoles to quinolines. chemrxiv.org/engage/chemr...

Post attachment
Jeff Lipshultz avatar
⟳ Gustafson Group @ Stony Brook retweeted
Jeff Lipshultz@jeflip·Feb 23

Our department (@StonyBrookChem) is looking for a PRODiG+ fellow – the appointment is two years, followed by conversion to a tenure-track assistant professor at the conclusion of the fellowship. A unique opportunity! apply.interfolio.com/178732